Ignite Creation Date:
2024-05-06 @ 1:34 PM
Last Modification Date:
2024-10-26 @ 1:16 PM
Study NCT ID:
NCT04068896
Status:
COMPLETED
Last Update Posted:
2024-07-09
First Post:
2019-08-22
Brief Title:
Study of NGM120 in Subjects With Advanced Solid Tumors Pancreatic Cancer and Prostate Cancer Using Combination Therapy
Sponsor:
NGM Biopharmaceuticals Inc
Organization:
NGM Biopharmaceuticals Inc
Study Overview
Official Title:
A Phase 12 Dose-Finding Study Followed by Expansion Cohorts of NGM120 a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study of NGM120 in subjects with advanced solid tumors and and pancreatic cancer Part 1 and 2 and metastatic castration resistant prostate cancer Part 3
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None